A two-phase epigenome-wide four-way gene-smoking interaction study of overall survival for early-stage non-small cell lung cancer
- PMID: 39630602
- PMCID: PMC11705728
- DOI: 10.1002/1878-0261.13766
A two-phase epigenome-wide four-way gene-smoking interaction study of overall survival for early-stage non-small cell lung cancer
Abstract
High-order interactions associated with non-small cell lung cancer (NSCLC) survival may elucidate underlying molecular mechanisms and identify potential therapeutic targets. Our previous work has identified a three-way interaction among pack-year of smoking (the number of packs of cigarettes smoked per day multiplied by the number of years the person has smoked) and two DNA methylation probes (cg05293407TRIM27 and cg00060500KIAA0226). However, whether a four-way interaction exists remains unclear. Therefore, we adopted a two-phase design to identify the four-way gene-smoking interactions by a hill-climbing strategy on the basis of the previously detected three-way interaction. One CpG probe, cg16658473SHISA9, was identified with FDR-q ≤ 0.05 in the discovery phase and P ≤ 0.05 in the validation phase. Meanwhile, the four-way interaction improved the discrimination ability for the prognostic prediction model, as indicated by the area under the receiver operating characteristic curve (AUC) for both 3- and 5-year survival. In summary, we identified a four-way interaction associated with NSCLC survival among pack-year of smoking, cg05293407TRIM27, cg00060500KIAA0226 and g16658473SHISA9, providing novel insights into the complex mechanisms underlying NSCLC progression.
Keywords: NSCLC; epigenomics; four‐way interaction; gene–smoking interaction.
© 2024 The Author(s). Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
References
-
- Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–263. - PubMed
-
- Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12–49. - PubMed
-
- Langer CJ, Besse B, Gualberto A, Brambilla E, Soria JC. The evolving role of histology in the management of advanced non‐small‐cell lung cancer. J Clin Oncol. 2010;28(36):5311–5320. - PubMed
MeSH terms
Grants and funding
- CA249096/US National Institutes of Health
- CA092824/US National Institutes of Health
- CA209414/US National Institutes of Health
- R01 CA249096/CA/NCI NIH HHS/United States
- ZCLY24H2601/Zhejiang Provincial Natural Science Foundation of China
- Qing Lan Project of the Higher Education Institutions of Jiangsu Province
- U01 CA209414/CA/NCI NIH HHS/United States
- ES000002/US National Institutes of Health
- R01 CA092824/CA/NCI NIH HHS/United States
- R35 CA197449/CA/NCI NIH HHS/United States
- P30 ES000002/ES/NIEHS NIH HHS/United States
- Outstanding Young Teachers Training Program of Nanjing Medical University
- 82273737/National Natural Science Foundation of China
- 82220108002/National Natural Science Foundation of China
- One Health Interdisciplinary Research Project of Ningbo University, Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)
LinkOut - more resources
Full Text Sources
Medical
